首页> 外文期刊>Optometry: Journal of the American Optometric Association >Steroid-induced ocular hypertension with loteprednol etabonate 0.2percent--A case report
【24h】

Steroid-induced ocular hypertension with loteprednol etabonate 0.2percent--A case report

机译:依托泊洛替诺酯0.2%类固醇性高眼压一例

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: The aim of this study was to present a case of a patient who showed a significant increase in intraocular pressure (IOP) with topical administration of loteprednol etabonate 0.2percent. CASE REPORT: A 29-year-old man administered 1 drop of loteprednol etabonate 0.2percent (Alrex~(~R)) to both eyes 4 times a day for 3 days as an off-label treatment for chronic red eye. By the third day of treatment, IOPs increased to 50 mmHg in each eye. The patient had no previous history of glaucoma. Gonioscopy found open angles in each eye. IOP returned to normal levels after discontinuation of Alrex. Steroid response in the same patient was confirmed on a second trial of Alrex. CONCLUSIONS: Although loteprednol etabonate has been shown to have a minimal effect on IOP in most patients, close follow-up is necessary whenever therapy is initiated.
机译:目的:本研究的目的是介绍一名患者,该患者在局部给予0.2%洛替泼诺依他博酯的情况下眼内压(IOP)显着升高。病例报告:一名29岁的男性每天两次给双眼施用1滴0.2%的洛替泼诺依托酸酯(Alrex〜(R)),连续3天,作为慢性红眼的不合用药治疗。到治疗的第三天,每只眼的IOP增至50 mmHg。该患者先前没有青光眼病史。角膜镜检查发现每只眼睛张开角度。 Alrex停用后,IOP恢复到正常水平。 Alrex的第二次试验证实了同一患者的类固醇反应。结论:尽管依托泊洛汀酯对大多数患者的眼压影响最小,但无论何时开始治疗,都必须进行密切随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号